Recro Pharma, Inc. operates as a specialty pharmaceutical company.
Reasonable growth potential and slightly overvalued.
Share Price & News
How has Recro Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RAH's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: RAH exceeded the German Pharmaceuticals industry which returned -9.1% over the past year.
Return vs Market: RAH exceeded the German Market which returned -17.5% over the past year.
Price Volatility Vs. Market
How volatile is Recro Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Recro Pharma undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: RAH (€5.85) is trading below our estimate of fair value (€43.7)
Significantly Below Fair Value: RAH is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: RAH is poor value based on its PE Ratio (38.8x) compared to the Pharmaceuticals industry average (19.6x).
PE vs Market: RAH is poor value based on its PE Ratio (38.8x) compared to the German market (16.3x).
Price to Earnings Growth Ratio
PEG Ratio: RAH is poor value based on its PEG Ratio (1.1x)
Price to Book Ratio
PB vs Industry: RAH has negative assets, so we can't compare its PB Ratio to the DE Pharmaceuticals industry average.
How is Recro Pharma forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RAH's forecast earnings growth (34.7% per year) is above the savings rate (-0.4%).
Earnings vs Market: RAH's earnings (34.7% per year) are forecast to grow faster than the German market (14.4% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: RAH's revenue (8.3% per year) is forecast to grow faster than the German market (4.1% per year).
High Growth Revenue: RAH's revenue (8.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RAH's Return on Equity is forecast to be high in 3 years time
How has Recro Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RAH has a high level of non-cash earnings.
Growing Profit Margin: RAH became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: RAH has become profitable over the past 5 years, growing earnings by -29.5% per year.
Accelerating Growth: RAH has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: RAH has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.9%).
Return on Equity
High ROE: RAH's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Recro Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: RAH has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: RAH has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: RAH has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: RAH's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Inventory Level: RAH has a high level of physical assets or inventory.
Debt Coverage by Assets: RAH has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RAH is profitable, therefore cash runway is not a concern.
Forecast Cash Runway: RAH is profitable, therefore cash runway is not a concern.
What is Recro Pharma's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RAH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate RAH's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RAH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RAH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RAH's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Gerri Henwood (67yo)
Dr. Geraldine A. Henwood, also known as Gerri, Ph.D., has been the President, Chief Executive Officer and Director of Baudax Bio Inc. since 2019. She has been the Chief Development Officer of Iomab-B at Ac ...
CEO Compensation Analysis
Compensation vs Market: Gerri's total compensation ($USD2.43M) is above average for companies of similar size in the German market ($USD731.58K).
Compensation vs Earnings: Gerri's compensation has been consistent with company performance over the past year.
|Chief Financial Officer||2.25yrs||US$784.13k||0.060% $104.8k|
|Senior Vice President of Development||12.25yrs||US$685.15k||no data|
|Chief Medical Officer||4.33yrs||US$1.18m||no data|
|Executive Vice President of Business Development||no data||no data||no data|
|Corporate Secretary||no data||no data||no data|
Experienced Management: RAH's management team is seasoned and experienced (8.2 years average tenure).
|Independent Director||12.25yrs||US$191.49k||0.083% $145.0k|
|Independent Chairman of the board||12.25yrs||US$209.99k||0.11% $197.2k|
|Independent Director||1.08yrs||no data||no data|
|Independent Director||11.25yrs||US$182.49k||0.083% $145.0k|
|Independent Director||6.08yrs||US$189.99k||0.083% $145.0k|
|Independent Director||3.08yrs||US$194.99k||0.064% $112.0k|
Experienced Board: RAH's board of directors are seasoned and experienced ( 11.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.5%.
Recro Pharma, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Recro Pharma, Inc.
- Ticker: RAH
- Exchange: BST
- Founded: 2007
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$191.629m
- Listing Market Cap: US$174.383m
- Shares outstanding: 23.46m
- Website: https://www.recropharma.com
Number of Employees
- Recro Pharma, Inc.
- 490 Lapp Road
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|REPH||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Mar 2014|
|RAH||BST (Boerse-Stuttgart)||Yes||Common Stock||DE||EUR||Mar 2014|
Recro Pharma, Inc. operates as a specialty pharmaceutical company. It operates through two divisions, an Acute Care, and Contract Development and Manufacturing (CDMO). The Acute Care division primarily focuses on developing products for the hospital and other acute care settings. The company’s lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has completed two pivotal Phase III clinical efficacy trials, a double-blind placebo-controlled Phase III safety trial, and four Phase II clinical efficacy trials, as well as other safety studies. Its pipeline also includes other early-stage product candidates, including two novel neuromuscular blocking agents and a related proprietary chemical reversal agent, and Dex-IN, a proprietary intranasal formulation of dexmedetomidine or Dex an alpha-2 adrenergic agonist. The CDMO division leverages its formulation expertise to develop and manufacture pharmaceutical products using its proprietary delivery technologies and other manufacturing services for commercial and development-stage partners who commercialize or plan to commercialize these products. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/01 04:36|
|End of Day Share Price||2020/03/31 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.